Record Quarterly Revenue
BrainsWay reported a record quarterly revenue of $13.5 million for Q3 2025, representing a 29% increase compared to the same period last year.
Increased Deep TMS Shipments
The company shipped 90 Deep TMS systems during the quarter, marking a 43% increase compared to the same period last year, bringing the total installed base to over 1,600 systems globally.
Raised Financial Guidance
BrainsWay raised its full-year 2025 revenue guidance to $51 million to $52 million, up from the previous guidance of $50 million to $52 million. Operating profit guidance was also increased to 6% to 7% of revenue.
FDA Approval for Accelerated Protocol
The U.S. FDA granted an expansion for the Deep TMS system to include an accelerated protocol for major depressive disorder, shortening the treatment phase significantly.
Successful Strategic Investments
The company made significant minority interest investments in mental health providers, seeing utilization of Deep TMS systems increase by over 50% in some clinics.
Strong Financial Performance
Gross profit for the quarter was $10.2 million, up from $7.7 million in the prior year, with a strong gross margin of 75%.